SCHEMBL3154754

SCHEMBL3154754

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.71
ALDH1A1 P00352 4/20 0.69
MEN1 O00255 3/20 0.69
BLM P54132 3/20 0.69
KMT2A Q03164 3/20 0.69
FAAH O00519 3/20 0.69
MAPT P10636 3/20 0.69
HPGD P15428 3/20 0.69
TDP1 Q9NUW8 3/20 0.69
KDM4E B2RXH2 2/20 0.69
USP2 O75604 2/20 0.69
CYP3A4 P08684 2/20 0.69
ALOX15 P16050 2/20 0.69
RECQL P46063 2/20 0.69
HSD17B10 Q99714 2/20 0.69
POLB P06746 1/20 0.69
APEX1 P27695 1/20 0.69
PMP22 Q01453 1/20 0.69
GPR18 Q14330 1/20 0.69
SLC6A5 Q9Y345 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928628 0.95 MEN1 (0.69) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL13400832 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL6891974 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL25712483 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL3492921 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL2680708 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL22190346 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
SCHEMBL15061596 0.89 HSP90AA1 (0.77) MEN1BLMKMT2AFAAHMAPT
Potassium SCHEMBL32681948 0.87 HSP90AA1 (0.74) MEN1BLMKMT2AFAAHMAPT
SCHEMBL3634730 0.86 CNR1 (0.71) CNR1ALDH1A1MEN1BLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511737-B1 ARYLOXIMES MERCK PATENT GMBH (DE) 2010-02-17 EP disclosed
EP-1509506-B1 PYRIDAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2009-08-05 EP disclosed
US-7563790-B2 Pyridazine derivatives MERCK PATENT GMBH (DE) 2009-07-21 US disclosed
US-7470687-B2 Aryl oximes MERCK PATENT GMBH (DE) 2008-12-30 US disclosed
US-20060270681-A1 Pyridazine derivatives EGGENWEILER HANS-MICHAEL 2006-11-30 US disclosed
US-7135471-B2 Aryl oximes MERCK PATENT GMBH (DE) 2006-11-14 US disclosed
US-7129241-B2 Pyridazine derivatives MERCK PATENT GESELLSCHAFT (DE) 2006-10-31 US disclosed
US-20060205708-A1 Aryl oximes EGGENWEILER HANS-MICHAEL 2006-09-14 US disclosed
US-20050209240-A1 Aryl oximes MERCK PATENT GMBH (DE) 2005-09-22 US disclosed
CN-1659147-A Pyridazine derivatives MERCK PATENT GMBH (DE) 2005-08-24 CN disclosed
WO-1990008545-A1 LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1990-08-09 WO disclosed
EP-0374602-A1 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1990-06-27 EP disclosed
US-4761403-A QUINOLONE DERIVATIVES ABBOTT LABORATORIES (US) 1988-08-02 US disclosed
EP-0240859-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1987-10-14 EP disclosed
US-4623661-A HYDROXAMIC ACID DERIVATIVES ABBOTT LABORATORIES (US) 1986-11-18 US disclosed
EP-0199152-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1986-10-29 EP disclosed
EP-0199153-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1986-10-29 EP disclosed
EP-0199151-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1986-10-29 EP disclosed
US-4608390-A ANTIINFLAMMORY, ANTIALLERGENS, ASTHMA, PSORIASIS, ARTHRITIS ABBOTT LABORATORIES (US) 1986-08-26 US disclosed
US-4605669-A Lipoxygenase inhibiting naphthohydroxamic acids ABBOTT LABORATORIES (US) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205708-A1 Aryl oximes PDE3B, CHRM1, MSR1 CNR1 701/4885ALDH1A1 1110/4885MEN1 3069/4885
US-20060270681-A1 Pyridazine derivatives PDE4A, PDE5A, PDE12 CNR1 1519/4885ALDH1A1 1898/4885MEN1 2466/4885
US-20050209240-A1 Aryl oximes PDE3B, CHRM1, MSR1 CNR1 701/4885ALDH1A1 1110/4885MEN1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.